1Olanow CW,Stern MB,Sethi K.The scientific and clinicalbasis for the treatment of Parkinson disease[J].Neurolo-gy,2009,72(21Suppl 4):S1-S136.
2Horstink M,Tolosa E,Bonuccelli U,et al.Review of thetherapeutic management of Parkinson,s disease.Report ofajoint task force of the European Federation of Neurolog-ical Societies and Movement Disorder Society-EuropeanSection.PartⅠ:early(uncomplicated)Parkinson's dis-ease[J].Eur J Neurol,2006,13(11):1170-1185.
3Piercey MF.Pharmacology of pramipexole,a dopamineD3-preferring agonist useful in treating Parkinson's dis-ease[J].Clin Neuropharmacol,1998,21(3):141-151.
4Maj J,Rogoi Z,Margas W,et al.The effect of repeatedtreatment with pramipexole on the central dopamine D3system[J].J Neural Transm,2000,107(12):1369-1379.
5Baronep M,Scarzella L,Marconi R,et al.Pramipexoleversus sertraline in the treatment of depression in Par-kinson's disease:a national multicenter parallel-grouprandomized study[J].J Neurol,2006,253(5):601-607.
6Zanettini R,Antonini A,Gatto G,et al.Valvular HeartDisease and the Use of Dopamine Agonists for Parkinson's disease[J].N Engl J Med,2007,356(1):39-46.
7Roth J,Ulmanova O,Ruzicka E.Organ changes inducedby ergot derivative dopamine agonist drug:time to changetreatment guide-line in Parkinson's disease[J].Cas LekCest,2005,144(2):123-126.
10Uberti D,Bianchi I,Olivari L,et al.Pramipexole preventneurotoxicity induced by oligomers of beta-amyloid[J].Eur J Pharmacol,2007,569(3):174-196.
二级参考文献20
1Maggio R, Scarselli M, Novi F, et al. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole [J]. J Neurochem, 2003,87 (3) :631-641.
2Okura T, Ito T, Ishiguro N, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist [J]. Life Sciences, 2007,80 (17) : 1564-1571.
3Parkison Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group [J]. JAMA, 2000,284(15):1931-198.
4Noyes K, Dick A W, Holloway R G. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life [ J ]. Value Health, 2006,9 ( 1 ) : 28- 38.
5Constantinescu R, Romer M, McDermott M P, et al. Impact of pramipexole on the onset of levodopa-related dyskinesias[J]. Mov Disord, 2007,22(9) : 1317-1319.
6Parkison Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage[J]. Clin Neuropharmacol, 2007,30(2) :72-85.
7Moller J C, Oertel W H, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial [ J ]. Mov Disord, 2005,20 (5) : 602- 610.
8Weiner W J, Factor S A, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease [J]. Parkinsonism Relat Disord, 2001,7(2) : 115-120.
9Zanettini R, Antonini A, Gatto G, et al. Valvular Heart Disease and the Use of Dopamine Agonists for Parkiuson's Disease [J]. N Engl J Med, 2007,356( 1 ) : 39-46.
10Linazasoro G. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease [ J ]. J Neurol, 2004,251 (3) : 335-339.
